PainChek iPad Consultation2

PainChek has started off the new Financial Year on a strong note, with a number of developments taking place across the quarter from July to September. We have continued to deliver growth in the Australian aged care sector, while also exploring opportunities in the home care, hospital, and disability segments, and progressing global expansion plans.

Continuing to strengthen PainChek’s foothold in the Australian aged care sector

PainChek has continued our positive growth trajectory in the Australian aged care sector. This means more aged care residents living with dementia and cognitive impairment are now benefiting from our pain assessment tool.

Between 1 July and 30 September 2020, we achieved:

• +8% increase in contracted clients, from 207 to 223
• +10% increase in Residential Aged Care facilities, from 722 to 795
• +9% growth in total contracted beds, from 61,571 to 66,887

At the end of September, there were approximately 67,000 aged care beds under license across nearly 800 aged care facilities. In addition, more than 190,000 clinical assessments have been completed as of 30 September 2020, a 41% growth in the quarter and 241% growth over the previous year — demonstrating PainChek®’s strong clinical utility and uptake in the residential aged care market.

This means that PainChek® is now the most common clinical software used in aged care facilities across Australia, with 25% of all existing aged care beds under contract and the ambition of reaching between 50-60% by June 2021.

According to CEO Philip Daffas:

“During 2020 and the COVID-19 pandemic there have been major challenges to the healthcare market and specifically the revision of attitudes and policies to the delivery of healthcare in aged care, home care and hospitals globally. We have continued to significantly grow our business during this year without being able to visit a single aged care facility and with the well documented lock downs around the world. We envisage stronger growth over the next period in our local market as Victoria comes out of lockdown and overseas as UK, European and North American markets now start to learn to live and manage ongoing business with the pandemic.”

Learn more about PainChek’s quarterly results in this presentation:

Giving a voice to those who cannot verbalise pain in the hospital, home care and disability segments

At PainChek, our mission is to give a voice to those who cannot verbalise pain. We began our journey in aged care as this is where the need is greatest. However, accurate pain assessment and treatment can also provide vast quality of life and quality of care improvements for individuals in a home care setting, hospital care setting, and those living with a disability.

    • Extending PainChek® into the home care setting: Three pilots in the $2 Billion Australian Home Care market now underway with leading Australian Home Care providers to support the increasing demand for home care service and packages. These home care pilots will conclude in January 2021, after which we will explore a broader market launch in Australia and overseas.
    • Improving pain detection in people with complex disabilities: PainChek has finalised a first commercial agreement in the disability sector with the Nulsen Group in Australia, for a pilot programme assessing pain in people living with disabilities and communication difficulties. This agreement is PainChek’s first with a National Disability provider (NDIS). Learn more about the partnership here.
    • Introducing better pain assessment tools for vulnerable populations in the hospital sector: PainChek has commenced a clinical study and commercial agreement with Ramsay Hospital Research group and Edith Cowan University for the use of PainChek® with frail patients in the Australian hospital sector. If successful, the first phase study can lead to broader adoption of PainChek® throughout the Ramsay hospital network, as well as potential national and international expansion. Learn more about the study here.

According to CEO Philip Daffas:

“It is well documented that elderly people living with dementia and cognitive impairment can rapidly move from home to an aged care facility and to hospital prior to returning home again. In addition, we now see carers and nurses transitioning between these three sectors and taking best practice across with them…PainChek has taken the opportunity to proactively deliver on these changing market dynamics and client needs. The Company has fully pivoted to a new safe and cost-effective business model that can be used globally, leveraging our fully digital capability to meet the ‘new norm’ of our three core global market opportunities.”

We are also continuing to make positive progress in our revised Children’s App clinical study, with a target of 2021 for TGA and CE Mark clearance.

Bringing PainChek® technology to more people worldwide with global market expansion

PainChek® is also moving forward on global market expansion, and key partnerships are now in place with market-leading clinical software providers in Canada and New Zealand.

In addition to pending regulatory clearance, PainChek has commenced a commercial partnership with AlayaCare, the leading Home Care software care management system provider in Canada. Under this agreement, PainChek and AlayaCare can collaboratively enter the Canadian home care market in early 2021, following the anticipated Health Canada regulatory clearance. This agreement can also be extended to AlayaCare US clients post-FDA clearance.

We have also expanded our presence in New Zealand with Medi-map Medication Management, the leading medication management software for aged care providers in New Zealand with access to 80% of the NZ market. PainChek® results link directly into the Medi-map platform to further enhance the seamless delivery of care for nurses and clinical staff.

The UK team are continuing to operate digitally whilst visitation to residential aged care facilities remains restricted as a result of the COVID-19 pandemic. Despite these challenging circumstances, PainChek continues to grow in the small and medium tiers, in particular with small and medium-sized facilities and facilities that have a speciality in dementia care. NHSX, the driver of digital transformation in the UK health and social care sector, has also cited PainChek UK as an AI-driven case study and Digital Social Care has also approved and subsequently posted a PainChek UK case study on their website.

More than pain assessment: PainChek® is key to future management in healthcare

PainChek® has become even more important and accessible during the COVID-19 pandemic, as evidenced by our continued growth for the first three quarters of 2020.

With over 190,000 paid assessments completed to date, PainChek® is more than just a pain assessment tool – it’s a critical tool for clinical decision-making at the provider, facility, and individual level.

Through the vast data housed securely on the PainChek® portal, we are able to provide comprehensive and valuable insights to our clients from the time and frequency of pain assessments to facility implementation. These empower providers to increase carer efficiency, deliver improved patient outcomes, and support best practice pain assessment.

Join hundreds of facilities benefitting from a free 12-month PainChek® license

To date, we have supported 123 residential aged care providers to fully implement PainChek® in their 315 facilities across the country. This has given thousands of Australians access to accurate pain assessment and improved treatment.

For a limited time only, the Federal Government initiative is available to all Australian residential aged care providers that have residents living with dementia or cognitive impairments. Register your interest today by filling out this form or calling 1800 098 809.

Latest News


PainChek (ASX:PCK) bringing a change to pain management

PainChek Limited (ASX:PCK) Managing Director and CEO, Philip Daffas discusses the company's PainChek facial recognition pain app, ..

Read More


Introducing the new PainChek® Shared Care Program

The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer, to extend their PainChek® license to a designated home-based family carer, so that they can…

Read More

AI Technology

The PainChek® Technology

AI Technology Redefining Pain Assessment PainChek® provides carers across multiple clinical areas with three important new clinical benefits; 1.  The ability to identify the presence of pain, when…

Read More